Metropolis Q4 Results Review - On The Path To Better Profitability: ICICI Securities

ICICI Securities Report

Metropolis Healthcare Ltd.’s Q4 FY24 results benefitted from a change in accounting year of its overseas subsidiary; adjusting for this, Metropolis’ result undershot our expectation marginally.

To further profitability, Metropolis took a ~4% price hike in January 2024; even so, volume growth (7% in Q4 FY24) has been steady. Impact of network expansion is in its last leg; it may add 25 labs in FY25E and 6–7 labs in FY26E.

Ebitda impact from new centres addition has softened, shrinking 30 bps QoQ in Q4 FY24. Via price hikes/better volumes, Metropolis is likely to restore its Ebitda margins to ~27–28% by FY26E.

Management is also actively pursuing an merger and acquisition, which may lift near-term earnings growth. We raise our FY26E Ebitda by ~5%. Retain Add with a higher DCF-based target price of Rs 2,160.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.